Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict psoriasis relapse after biologics? a new study digs into the clues.

NCT ID NCT07730619

Knowledge-focused Sponsor: First Affiliated Hospital Xi'an Jiaotong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This study investigates why some people with plaque psoriasis experience a relapse after treatment with biologic drugs, while others do not. Researchers will compare patients who relapsed with those who did not, looking at factors like age, lifestyle, lab results, and treatment history. The goal is to identify warning signs and evaluate which follow-up treatments work best after a relapse.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
biologic agents (e.g., adalimumab) for plaque psoriasis
What this could lead to
If successful, this could help doctors predict which psoriasis patients are likely to relapse after biologic therapy and choose the best next treatment.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients or biologics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study retrospectively selected plaque psoriasis patients who received biologic treatment in the dermatology department of our hospital from December 2022 to December 2024.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed as plaque psoriasis. * Received biological therapy for more than six months. * Voluntarily participate in this study, with normal communication and understanding abilities. * Recurrent group: Patients with initial treatment effective (PGA or BSA improvement reduced by more than 75% from baseline), PGA ≥ 3 or BSA decreased by less than 50% from baseline after a period of time \[218\], and who were treated in the dermatology department of our hospital. * Control group: Treatment effective (PGA maintained at 0/1 or BSA improvement decreased by more than 75% from baseline), and no recurrence as mentioned in ④ occurred. Exclusion Criteria: * Patients with other types of psoriasis. * Pregnant patients * Patients who refuse to cooperate with medical staff questionnaire surveys or refuse to provide auxiliary testing or examination materials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biologic agents are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biologic agents Influence factors Plaque psoriasis Relapse

Contacts and locations

Locations

  • Dermatology Department of the First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, 710061, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.